NASDAQ NMS - GLOBAL MARKET · ALT
-1.89% · -$0.0500 · Vol 4.9M
Market closed · last close 4:00 PM ET · price as of 18:25:56 ET
Altimmune Inc

Altimmune Inc

Biotechnology
$2.61
Card
Relationship Map

Follow $ALT

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ALT by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
ALT
Altimmune Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

68/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALT catalysts
About Altimmune Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2005
Employees
57
Country
US

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.66
Day high
$2.66
Day low
$2.55
Previous close
$2.66
52W high
$6.18
-57.77% from high
52W low
$2.55
2% of range
Market cap
$517.4M
EPS
$-0.7755
Beta
1.26
Shares out
194.5M
Volume
4.9M
1.26× rel vol
Avg volume
3.9M
VWAP
$2.59
Price history computed in-house
1W
-4.58%
1M
-22.10%
3M
-14.43%
1Y
-34.76%
YTD
-27.71%
SMA 50 $3.07 · below
SMA 200 $3.42 · below
52W position 2%

ALT overview

Veridion Score
68
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALT Form 4 filings
Public disclosures

Congress activity in ALT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ALT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALT in this window.
Lobbying spend

ALT lobbying filings, year to date.

Registered lobbying filings matched to Altimmune Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALT in this window.
Loading news for ALT
Analyst ratings
Sovereign unlock shows live analyst consensus for ALT.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.